Mersana Therapeutics stock recently experienced a shift in analyst price targets, following fresh developments in the company’s acquisition narrative. While the fair value has held steady at $33.20 ...

PIN-5018 achieves complete response in ACC PDX models Expansion planned into mCRPC, colorectal cancer, and other rare tumours ...

Day One Biopharmaceuticals has seen its consensus analyst price target trimmed from $24.25 to $22.25. This is a signal that market sentiment has turned more cautious on the stock's near-term outlook.

The firm plans to explore biomarkers of response for PIN-5018 and its other pipeline candidates to identify best responders to treatment.

Pin Therapeutics, a clinical-stage biotechnology company specializing in targeted protein degradation, announced on November 20 that it has administered the first dose of its CK1α-selective degrader ...

Phin Therapeutics, a company specializing in protein degradation-based drug development, announced on November 20 that it has begun dosing the first ...

Lindberg was diagnosed with adenoid cystic carcinoma (ACC), which the Cleveland Clinic describes as a “rare type of cancer ...

Q3 2025 Earnings Call Transcript November 14, 2025 MiNK Therapeutics, Inc. beats earnings expectations. Reported EPS is ...

Detailed price information for Day One Biopharmaceuticals Inc (DAWN-Q) from The Globe and Mail including charting and trades.

Oppenheimer analyst Matthew Biegler notes Day One (DAWN) announced it was acquiring Mersana Therapeutics (MRSN) for its B7-H4 ADC being tested in ...

Day One Biopharmaceuticals has struck a deal to buy fellow biopharmaceutical company Mersana Therapeutics for up to $285 million in cash. Day One on Thursday said it will pay an initial $25 a share, ...

Rates of one type of breast cancer — invasive lobular carcinoma — have been rising in the United States more than three times faster than those of all other breast cancers combined over the past ...